Navigation Links
Dendreon Appoints Hans Bishop as Chief Operating Officer
Date:12/10/2009

SEATTLE, Dec. 10 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Hans Bishop has joined the Company as chief operating officer, effective January 4, 2010. Mr. Bishop most recently served as president of the specialty medicine business at Bayer, where he was responsible for a diverse portfolio of oncology, hematology, and neurology products. Mr. Bishop also served as an executive vice president of Bayer HealthCare LLC.

As a member of the Dendreon executive management team, Mr. Bishop will be responsible for preparing for and leading the commercial launch of PROVENGE® (sipuleucel-T), including sales and marketing, as well as manufacturing, supply chain, quality, and facilities engineering.

"Hans' extensive and successful global commercial experience will add tremendous value to Dendreon's already strong executive team as we prepare for the launch of PROVENGE in the coming year," said Mitchell H. Gold, M.D., president and chief executive officer. "Hans' deep knowledge of sales and marketing, manufacturing and operations will be integral to our success as we transform Dendreon into a commercial organization and work to fulfill our mission of transforming the lives of patients with cancer."

During his tenure leading specialty medicine at Bayer HealthCare, Mr. Bishop grew the specialty medicine business into a euro 3 billion global franchise, including overseeing the successful growth of Nexavar® and the significant expansion of the company's oncology pipeline. Prior to this position, Mr. Bishop served at Chiron Corporation as senior vice president of global commercial operations, as well as vice president and general manager of European biopharmaceuticals. In these roles, Mr. Bishop was responsible for commercial operations for the Global Biopharmaceuticals Division, leading country operations and programs such as new product development and pricing.

Earlier in his career, Mr. Bishop served in roles of increasing responsibility that included sales and marketing as well as business development at Glaxo Wellcome and SmithKline Beecham. He also spent four years as the executive vice president of operations with a global telecom service company, where he managed nine subsidiaries on three continents, before facilitating the sale of the company in 2004.

Mr. Bishop received a B.S. in chemistry from Brunel University in London.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce ACI product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington, and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.

SOURCE Dendreon Corporation


'/>"/>
SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ), the leader ... Lanphier , Sangamo,s president and chief executive officer, will ... Therapeutic ® development programs and an overview of ... Thursday, February 11, 2016, at the Leerink Partners 5 ... being held in New York . ...
(Date:2/4/2016)... and MENLO PARK, Calif. , Feb. ... ("DelMar" and the "Company"), a biopharmaceutical company focused on the ... it will present at the 18 th Annual ... 2016 at 10:00 a.m. EST in New York, ... president and CEO, will provide an update on the ongoing ...
(Date:2/4/2016)... (PRWEB) , ... February 04, 2016 , ... ... (AI) and leading supplier of Semantic Graph Database technology has been recognized As ... Products ” by Corporate America Magazine. , “At Corporate America, it’s our priority ...
(Date:2/3/2016)... 2016  With the growing need for better ... underway, therapies such as monoclonal antibodies, recombinant protein ... of indications are in high demand. Conventionally expression ... and production of these therapeutics. However, due to ... costs, novel approaches and novel expression systems are ...
Breaking Biology Technology:
(Date:1/25/2016)... Jan. 25, 2016   Unisys Corporation (NYSE: UIS ... F. Kennedy (JFK) International Airport, New York City ... identify imposters attempting to enter the United States ... them. pilot testing of the system at Dulles ... terminals at JFK during January 2016. --> pilot testing ...
(Date:1/22/2016)... DUBLIN , Jan. 22, 2016 /PRNewswire/ ... announced the addition of the "Global ... report to their offering. --> ... of the "Global Biometrics Market in ... offering. --> Research and ...
(Date:1/20/2016)... MINNETONKA, Minn. , Jan. 20, 2016   ... that supports the entire spectrum of clinical research, is ... in 2015. MedNet,s significant achievements are the result of ... of) iMedNet eClinical , it,s comprehensive, ... --> --> Key MedNet growth ...
Breaking Biology News(10 mins):